41 Will the use of high sensitivity troponin result in overdiagnosis of myocardial infarction?

J. Doust, P. Glasziou
{"title":"41 Will the use of high sensitivity troponin result in overdiagnosis of myocardial infarction?","authors":"J. Doust, P. Glasziou","doi":"10.1136/bmjebm-2018-111070.41","DOIUrl":null,"url":null,"abstract":"Objectives The introduction of high sensitivity troponin (hs-Tn) redefines who is diagnosed with myocardial infarction (MI) and may increase the incidence of MI. The Preventing Overdiagnosis Working Group of the Guidelines International Network recently published a checklist for groups seeking to modify a disease definition in 2017. We used the checklist to determine if this clarifies the harms and benefits of the new test in the diagnosis of MI. Method We assessed the evidence for hs-Tn against each of the questions in the 8-item checklist:Differences between the previous and the new definitionChanges to the incidence and prevalence of the diseaseTrigger for considering the modificationDoes it predict clinically important outcomes compared with the previous definition?What is the repeatability, reproducibility, and accuracy of the new disease definition?Benefit: What is the incremental benefit for patients?Harm: What is the incremental harm for patients?What is the net benefit and harm for patients? Results hs-Tn has higher analytical sensitivity, which allows myocardial infarction to be diagnosed earlier and treatment commenced. Patients with low levels at 4 hours can be safely discharged. hs-Tn also is predictive of clinically important outcomes and has higher precision than earlier forms of the troponin. Maintaining the 99th centile as the threshold for diagnosis of myocardial infarction and the methods used in studies to determine the reference limit leads to an increase in the numbers of people diagnosed with myocardial infarction, with significant differences between studies depending on the types of patients being tested. The evidence for assessing the benefits and harms of hs-Tn is limited, limited to a before-after study showing an improvement in health outcomes. The introduction of hs-Tn in Australia earlier than in the US may explain the divergence in the incidence of non-ST elevation myocardial infarction in the two countries. Conclusions The example of hs-Tn illustrates that rigorous evaluations of disease definitions cannot be isolated from the tests used to diagnose that disease. Despite the significant consequences from the introduction of the test and the potential for overdiagnosis, it has been introduced because of improvements in analytical performance rather than on a thorough evaluation of potential harms and benefits.","PeriodicalId":298595,"journal":{"name":"BMJ Evidenced-Based Medicine","volume":"58 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Evidenced-Based Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjebm-2018-111070.41","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives The introduction of high sensitivity troponin (hs-Tn) redefines who is diagnosed with myocardial infarction (MI) and may increase the incidence of MI. The Preventing Overdiagnosis Working Group of the Guidelines International Network recently published a checklist for groups seeking to modify a disease definition in 2017. We used the checklist to determine if this clarifies the harms and benefits of the new test in the diagnosis of MI. Method We assessed the evidence for hs-Tn against each of the questions in the 8-item checklist:Differences between the previous and the new definitionChanges to the incidence and prevalence of the diseaseTrigger for considering the modificationDoes it predict clinically important outcomes compared with the previous definition?What is the repeatability, reproducibility, and accuracy of the new disease definition?Benefit: What is the incremental benefit for patients?Harm: What is the incremental harm for patients?What is the net benefit and harm for patients? Results hs-Tn has higher analytical sensitivity, which allows myocardial infarction to be diagnosed earlier and treatment commenced. Patients with low levels at 4 hours can be safely discharged. hs-Tn also is predictive of clinically important outcomes and has higher precision than earlier forms of the troponin. Maintaining the 99th centile as the threshold for diagnosis of myocardial infarction and the methods used in studies to determine the reference limit leads to an increase in the numbers of people diagnosed with myocardial infarction, with significant differences between studies depending on the types of patients being tested. The evidence for assessing the benefits and harms of hs-Tn is limited, limited to a before-after study showing an improvement in health outcomes. The introduction of hs-Tn in Australia earlier than in the US may explain the divergence in the incidence of non-ST elevation myocardial infarction in the two countries. Conclusions The example of hs-Tn illustrates that rigorous evaluations of disease definitions cannot be isolated from the tests used to diagnose that disease. Despite the significant consequences from the introduction of the test and the potential for overdiagnosis, it has been introduced because of improvements in analytical performance rather than on a thorough evaluation of potential harms and benefits.
使用高敏感性肌钙蛋白会导致心肌梗死的过度诊断吗?
高敏感性肌钙蛋白(hs-Tn)的引入重新定义了谁被诊断为心肌梗死(MI),并可能增加MI的发病率。指南国际网络预防过度诊断工作组最近发布了一份清单,供寻求在2017年修改疾病定义的团体使用。我们使用清单来确定这是否澄清了新检测在心肌梗死诊断中的危害和益处。方法我们根据8项清单中的每个问题评估hs-Tn的证据:旧定义与新定义之间的差异;疾病发病率和流行率的变化;考虑修改的触发因素;与旧定义相比,它是否预测临床重要结果?新疾病定义的可重复性、再现性和准确性是什么?益处:对患者的增量益处是什么?危害:对患者的增量危害是什么?对患者的净收益和伤害是什么?结果hs-Tn具有较高的分析灵敏度,有利于心肌梗死的早期诊断和治疗。4小时低水平患者可安全出院。hs-Tn也可以预测临床重要结果,比早期形式的肌钙蛋白具有更高的准确性。维持第99个百分位作为心肌梗死诊断的阈值,以及研究中确定参考限的方法导致心肌梗死诊断人数的增加,根据被检测患者的类型,研究之间存在显著差异。评估hs-Tn利弊的证据有限,仅限于显示健康结果改善的前后对照研究。澳大利亚比美国更早引入hs-Tn可能解释了两国非st段抬高型心肌梗死发病率的差异。hs-Tn的例子说明,不能将对疾病定义的严格评估与用于诊断该疾病的测试分离开来。尽管该测试的引入带来了重大后果和过度诊断的可能性,但它的引入是因为分析性能的提高,而不是对潜在危害和益处的全面评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信